Ratio Between Metastatic and Examined Lymph Nodes Is an Independent Prognostic Factor After D2 Resection for Gastric Cancer: Analysis of a Large European Monoinstitutional Experience

From the Department of Oncological and Surgical Science, University of Padova, Italy.

Address correspondence and reprint requests to: Donato Nitti, MD, Istituto di Clinica Chirurgica Generale II, Università di Padova, Via Giustiniani, 2, 35128 - Padova, Italy; Fax: 39-049-651891.

	Abstract

Background: In view of the lack of consensus on the level and number of lymph nodes to be examined for accurate staging of patients with gastric cancer, our aim was to evaluate the prognostic significance of lymph node status in a large European monoinstitutional experience.

Methods: A review was made of our prospective database from 1980 to 2000, when 314 of 445 patients operated for gastric adenocarcinoma underwent radical resection (R0) with D2 lymphadenectomy. Survival was determined by the Kaplan-Meier method and differences were assessed by the log-rank test. Multivariate analysis was performed using the Cox proportional hazards model in forward stepwise regression.

Results: In 277 evaluable patients, 5-year survival was 57% (median follow-up, 48 months; range, 2-251). A total of 7668 lymph nodes were examined (median, 27; range, 11-62). The 5-year survivals according to the metastatic/examined lymph nodes ratio (N ratio) were 14%, 50%, 61%, and 82% in the group of patients with N ratio >25%, 11%-25%, 1%-10%, and 0%, respectively (P < .0001). At multivariate analysis, the N ratio was the best single independent prognostic factor (P = .000).

Conclusions: After R0 resection for gastric cancer, the N ratio is a potent prognostic factor. It should therefore be considered in the clinical decision making process.

Key Words: Gastric cancer, Lymphadenectomy, Prognostic factor, Staging, Lymph nodes ratio

This article has been cited by other articles:

				J. Peng, Y. Xu, Z. Guan, J. Zhu, M. Wang, G. Cai, W. Sheng, and S. Cai Prognostic Significance of the Metastatic Lymph Node Ratio in Node-Positive Rectal Cancer Ann. Surg. Oncol., November 1, 2008; 15(11): 3118 - 3123. [Abstract] [Full Text] [PDF]

				M. Falconi, S. Crippa, I. Dominguez, G. Barugola, P. Capelli, S. Marcucci, S. Beghelli, A. Scarpa, C. Bassi, and P. Pederzoli Prognostic Relevance of Lymph Node Ratio and Number of Resected Nodes after Curative Resection of Ampulla of Vater Carcinoma Ann. Surg. Oncol., November 1, 2008; 15(11): 3178 - 3186. [Abstract] [Full Text] [PDF]

				X. Wang, J.-J. Wang, and F. Wan A Common Misuse of Stepwise Regression in Studies of Ratio of Metastatic Lymph Nodes for Gastric Cancer Ann. Surg. Oncol., June 1, 2008; 15(6): 1805 - 1806. [Full Text] [PDF]

				C. R. Rossi, S. Mocellin, S. Pasquali, P. Pilati, and D. Nitti N-Ratio: a Novel Independent Prognostic Factor for Patients with Stage-III Cutaneous Melanoma Ann. Surg. Oncol., January 1, 2008; 15(1): 310 - 315. [Abstract] [Full Text] [PDF]

				H.-Y. Lee, H.-J. Choi, K.-J. Park, J.-S. Shin, H.-C. Kwon, M.-S. Roh, and C. Kim Prognostic Significance of Metastatic Lymph Node Ratio in Node-Positive Colon Carcinoma Ann. Surg. Oncol., May 1, 2007; 14(5): 1712 - 1717. [Abstract] [Full Text] [PDF]

				A. Marchet, S. Mocellin, C. Belluco, A. Ambrosi, F. DeMarchi, E. Mammano, M. Digito, A. Leon, A. D'Arrigo, M. Lise, et al. Gene Expression Profile of Primary Gastric Cancer: Towards the Prediction of Lymph Node Status Ann. Surg. Oncol., March 1, 2007; 14(3): 1058 - 1064. [Abstract] [Full Text] [PDF]

				J.-H. Cheong, W. J. Hyung, J. G. Shen, C. Song, J. Kim, S. H. Choi, and S. H. Noh The N Ratio Predicts Recurrence and Poor Prognosis in Patients With Node-Positive Early Gastric Cancer Ann. Surg. Oncol., March 1, 2006; 13(3): 377 - 385. [Abstract] [Full Text] [PDF]

				D. D. Smith, R. R. Schwarz, and R. E. Schwarz Impact of Total Lymph Node Count on Staging and Survival After Gastrectomy for Gastric Cancer: Data From a Large US-Population Database J. Clin. Oncol., October 1, 2005; 23(28): 7114 - 7124. [Abstract] [Full Text] [PDF]

				O. Bouche, M. Ychou, P. Burtin, L. Bedenne, M. Ducreux, G. Lebreton, J. Baulieux, B. Nordlinger, C. Martin, J. F. Seitz, et al. Adjuvant chemotherapy with 5-fluorouracil and cisplatin compared with surgery alone for gastric cancer: 7-year results of the FFCD randomized phase III trial (8801) Ann. Onc., September 1, 2005; 16(9): 1488 - 1497. [Abstract] [Full Text] [PDF]

				M. D. McKee and M. C. Posner The Staging of Gastric Cancer: Nothing Novel but Perhaps Better Ann. Surg. Oncol., November 1, 2003; 10(9): 1005 - 1006. [Full Text] [PDF]